ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq (OPTIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00234533
Recruitment Status : Completed
First Posted : October 7, 2005
Results First Posted : August 9, 2018
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Ipsen

Brief Summary:
The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.

Condition or disease Intervention/treatment Phase
Turner Syndrome Renal Insufficiency, Chronic Pituitary Diseases Dwarfism Drug: Somatropin (rDNA origin) Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 251 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIIB, International, Single Group, Open Study to Define an Optimal Monitoring of IGF-1 in Children Treated With NutropinAq, Using a Novel Capillary Blood Collection Method
Study Start Date : June 2004
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008


Arm Intervention/treatment
Experimental: NutropinAq 10 mg/2 mL (30 IU)

Patients received daily subcutaneous (s.c.) injections of NutropinAq 10 milligrams (mg)/2 milliliters (mL) for 6 months. The therapeutic daily doses administered were as follows:

  • GHD patients: 0.025 - 0.035 mg/ kilogram (kg) bodyweight
  • TS patients: up to 0.05 mg/kg bodyweight
  • CRI patients: up to 0.05 mg/kg bodyweight

Patients visited the study clinic for a baseline visit and for 2 other visits every 3 months (Weeks 12 and 24). Additional home assessments were made at Weeks 21, 22 and 23.

The investigator determined the dose administered to each patient, and it was recommended to perform the injection in the evening.

Drug: Somatropin (rDNA origin)
Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.




Primary Outcome Measures :
  1. Insulin-Like Growth Factor I (IGF-I) Levels Measured Using the Timed Capillary Blood Spot Samples [ Time Frame: At Weeks 21, 22 and 23 ]

    Fingertip capillary blood was collected using filter paper cards for the assay of capillary blood spot IGF-I in line with the monitoring recommendations of the Lawson Wilkins Paediatric Endocrine Society (LWPES) for treatment with recombinant GH therapy in children.

    Capillary IGF-I assays were performed by the patient at home one day per week during Weeks 21, 22 and 23 only (same week day). The samples were scheduled in the evening prior to the injection of NutropinAq and between 7:00 and 9:00 the following morning. An extended window from 6:00 to 12:00 was allowed for defining protocol deviations.

    The number of capillary blood spot IGF-I measurements and the optimal timing of samples to assess the IGF-I status of NutropinAq treated patients was assessed. IGF-I measurements for the morning and evening sampling are presented.



Secondary Outcome Measures :
  1. Assessment of IGF-I Levels: Categorised by Weekly Timing (Weeks 21-23) and Daily Timing (Morning and Evening) [ Time Frame: At Weeks 21, 22 and 23 ]
    The influence of daily and weekly timing on the IGF-I value as measured using the capillary blood spot method was analysed. A 3-way analyses of variance (ANOVA) was performed with patient, day and daily timing as factors after appropriate transformation to obtain normally distributed parameters. The interaction day*time was tested and kept in the model only if p-value<0.1. Parameter estimates from the statistical model are presented as least squares means for the categories of daily timing (Morning and Evening) and weekly timing (Week 21, Week 22 and Week 23). The values reported for Week 21, 22, and 23 represent the average IGF-I levels from the morning and evening samples at each week. The values reported for Evening represent the Evening IGF-I levels averaged across Weeks 21, 22, and 23, and similarly for the Morning values.

  2. Assessment of IGF-I Levels: Categorised by Sex and Prepubertal Status [ Time Frame: At Weeks 21, 22 and 23 ]
    The influence of sex and prepubertal status on the IGF-I value as measured using the capillary blood spot method was analysed. Parameter estimates from the statistical model are presented as least squares means for the categories of sex (male and female) and prepubertal status (pubertal and prepubertal). The values reported represent average IGF-I levels as determined from the 6 measurements taken (i.e. morning and evening samples at Weeks 21, 22 and 23).

  3. Multivariate Linear Regression Analyses to Assess Factors Affecting the Variability of IGF-I Levels: Categorised by Disease Condition and Location [ Time Frame: Up to Week 24 ]

    A multivariate linear regression analysis of factors on within-subject coefficient of variation (WCV) using a stepwise forward-backward elimination was used to determine the effect of individual factors on IGF-I values as measured using the capillary blood spot method (p=0.15 for a variable to enter and remain in the model). The WCV was computed from the series of 6 measurements (2 samplings in each of Weeks 21, 22 and 23). The influence of disease condition and country clusters on the IGF-I value were assessed.

    Country clusters: cluster 1: France; cluster 2: Spain, Greece, Romania and Italy; cluster 3: UK, Belgium, Czech Republic, Denmark, Germany, Slovakia, Austria and Finland ; cluster 4: Russia ; cluster 5: Ukraine.

    Parameter estimates from the statistical model presented as least squares means for categories of disease condition (GHD and TS) and location (Clusters 1, 2, 3, 4 and 5) are presented.


  4. Multivariate Linear Regression Analyses to Assess Factors Affecting the Variability of IGF-I Levels: Categorised by Time of Year, Calculated Age at Enrolment and Disease Condition [ Time Frame: Up to Week 24 ]

    A multivariate linear regression analysis of factors on WCV using a stepwise forward-backward elimination was used to determine the effect of individual factors on IGF-I values as measured using the capillary blood spot method (p=0.15 for a variable to enter and remain in the model). The WCV was computed from the series of 6 measurements (2 samplings in each of Weeks 21, 22 and 23). The influence of the time of the year (1st, 2nd, 3rd and 4th quarters), calculated age at enrolment and disease condition on the IGF-I value were assessed.

    Parameter estimates from the statistical model are presented as least squares means for the categories of time of the year (1st, 2nd, 3rd and 4th quarters), calculated age at enrolment and disease condition (GHD and TS).


  5. Change From Baseline at Week 24 in the IGF-I Levels as Measured by Capillary Blood Spot Method and Serum IGF-I Assay [ Time Frame: Baseline to Week 24 ]

    3 simultaneous IGF-I measurements were taken at Weeks 0 (baseline), 12 and 24 by serum and capillary assay to determine the precision profile of the capillary blood spot method versus the serum IGF-I assay.

    Change from baseline at Week 24 in the IGF-I measurements by capillary blood spot method and serum assay are presented.


  6. Change From Baseline at Week 12 and Week 24 in Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Measurements [ Time Frame: Baseline to Week 12 and Week 24 ]

    The LWPES recommends that treatment for any indication with recombinant GH therapy in children be accompanied by regular monitoring of IGF-I and IGFBP3 concentrations. IGFBP3 binds circulating IGF-I and serum samples were taken at Visit 1 (Week 0), Visit 2 (Week 12) and Visit 3 (Week 24) in order to measure IGFBP3.

    Change from baseline (Visit 1) at Visits 2 and 3 in IGFBP3 is presented.


  7. Change From Baseline at Week 24 in the Auxological Parameter Height [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, height, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).

    Change from baseline in measured height at Visit 3 (Week 24) for the overall ITT population is presented.


  8. Change From Baseline at Week 24 in the Auxological Parameter Calculated Height SDS [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, height, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Height SDS = (height - reference mean height (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in growth, therefore, a favorable outcome.

    Change from baseline in the calculated height SDS at Visit 3 (Week 24) for the overall ITT population is presented.


  9. Change From Baseline at Week 24 in the Auxological Parameter Weight [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, weight, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).

    Change from baseline in measured weight at Visit 3 (Week 24) for the overall ITT population is presented.


  10. Change From Baseline at Week 24 in the Auxological Parameter Calculated Weight SDS [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, weight, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Weight SDS = (weight - reference mean weight (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in weight, therefore, a favorable outcome.

    Change from baseline in the calculated weight SDS at Visit 3 (Week 24) for the overall ITT population is presented.


  11. Change From Baseline at Week 24 in the Auxological Parameter Annualised Growth Velocity [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, annualised growth velocity, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24).

    Change from baseline in the measured annualised growth velocity at Visit 3 (Week 24) for the overall ITT population is presented.


  12. Change From Baseline at Week 24 in the Auxological Parameter Annualised Growth Velocity SDS [ Time Frame: Baseline to Week 24 ]

    The auxological parameter, annualised growth velocity, was measured at Visit 1 (Baseline measurement), Visit 2 (Week 12) and Visit 3 (Week 24). The French growth charts were used for the calculation of SDS parameters: the charts provide for each age range and sex a mean parameter and SD value, from which the SDS parameter can be derived assuming a normal distribution. For example: Annualised GV SDS = (annualised GV - reference mean annualised GV (age, sex)) / reference SD (age, sex). The SDS indicates the number of standard deviations away from the mean. A SDS of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A positive change in SDS indicates an improvement in growth velocity, therefore, a favorable outcome.

    Change from baseline in the annualised growth velocity SDS at Visit 3 (Week 24) for the overall ITT population is presented.


  13. Percentage of Patients Rating the Overall Handling of the Administration Device, NutropinAq Pen, to Assess the Acceptability and Tolerance of NutropinAq and Its Pen [ Time Frame: At Month 5 ]

    The acceptability was evaluated by a questionnaire at Month 5. The users (parents and/or child) of NutropinAq pen and compliance aid booklet were asked to describe and rate the pen, cartridge, compliance aid booklet and their ease of use.

    The percentage of patients responding to each category for the assessment of the overall handling of the NutropinAq pen are presented. The categories are: Very easy, Easy, Moderately difficult, Difficult, Very difficult and Missing.


  14. Posology of NutropinAq at Baseline (Visit 1) Summarised as Mean Dose [ Time Frame: Visit 1 (Baseline) ]
    It was intended that the posology (mg/kg/day) of NutropinAq would remain constant throughout the study. The mean posology adopted at Visit 1 is presented.

  15. Extent of Exposure to NutropinAq Throughout the Study [ Time Frame: Up to Week 24 ]
    The extent of treatment exposure throughout the study is presented as the mean number of daily injections performed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Children under 18 with growth failure associated with inadequate growth hormone secretion, or Turner syndrome or chronic renal insufficiency.

Exclusion Criteria:

  • Children with closed epiphyses
  • Children with active neoplasm
  • Children with acute critical illness

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234533


  Show 45 Study Locations
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Pascale Dutailly, MD Ipsen

Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT00234533     History of Changes
Other Study ID Numbers: 2-79-58035-700
First Posted: October 7, 2005    Key Record Dates
Results First Posted: August 9, 2018
Last Update Posted: August 9, 2018
Last Verified: November 2017

Keywords provided by Ipsen:
growth
child development
growth hormone
inadequate growth hormone secretion
growth failure

Additional relevant MeSH terms:
Dwarfism
Renal Insufficiency
Turner Syndrome
Gonadal Dysgenesis
Primary Ovarian Insufficiency
Renal Insufficiency, Chronic
Pituitary Diseases
Kidney Diseases
Urologic Diseases
Disorders of Sex Development
Urogenital Abnormalities
Sex Chromosome Disorders of Sex Development
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Sex Chromosome Disorders
Chromosome Disorders
Genetic Diseases, Inborn
Gonadal Disorders
Endocrine System Diseases
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Hypothalamic Diseases
Brain Diseases